Open AccessCandesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study
Author(s) -
Akihiko Takahashi,
Hiroyuki Takase,
Takayuki Toriyama,
Tomonori Sugiura,
Yutaka Kurita,
Ryuzo Ueda,
Yasuaki Dohi
Publication year - 2006
Publication title -
nephrology, dialysis, transplantation/nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfl293
Subject(s) - candesartan , medicine , cardiology , heart failure , myocardial infarction , clinical endpoint , angiotensin ii , angiotensin receptor , randomized controlled trial , blood pressure
Cardiovascular events are the major determinants of the prognosis of patients on chronic haemodialysis. The present study was designed to investigate whether candesartan, an angiotensin II type-1 receptor blocker, reduces the incidence of cardiovascular events in these patients.